Past performance does not predict future results. Informational only, not investment advice.
INTS has a novel tumor treatment breakthrough in FDA trials with major pharma partners, recently raised cash through 2027, and is trading 50% below the capital raise price at only $25M market cap. Author expects 10-20x returns within 18 months.
Intensity Therapeutics has a revolutionary non-covalent drug delivery platform for cancer with phase 3 readout and FDA approval as catalysts years ahead. Current 50M market cap with a 20-100x upside target upon approval driven by the delivery platform's potential to enable multiple drugs and address previously unusable toxic therapeutics.
Intensity Therapeutics has published peer-reviewed clinical evidence showing their intratumoral cancer therapy achieved 18-month median survival versus 3 months with standard therapy and 83% disease control versus 50% with existing treatments in heavily pretreated patients across 20+ cancer types. The company has potential for acquisition by major pharma and represents a paradigm shift from systemic chemotherapy to localized treatment with minimal side effects.
End of results.